Longitudinal assessment of the circulating cytokine profile of severe alcohol-associated hepatitis.
David Tornai, Mack C Mitchell, Craig J McClain et al.
✦ AI-curated · Sources linked
In 30 seconds
This longitudinal biomarker analysis used samples from 89 patients with severe alcohol-associated hepatitis (MELD≥20) enrolled in a multicenter, double-blind randomized trial comparing anakinra-based treatment with methylprednisolone plus placebo. Investigators measured 43 plasma indicators at enrollment and days 7, 28, 90, and 180, with 27 healthy controls for comparison. Biomarker profiles differed from healthy controls and changed over time and by treatment group. In survivors, dysregulated markers generally trended toward improvement, but most had not normalized by day 180. Markers associated with 90-day mortality were largely treatment-specific.
Key findings
- The study included 89 patients across 4 US sites and assessed 43 plasma indicators at days 0, 7, 28, 90, and 180.
- Day 7 IL-1Ra levels rose significantly in the anakinra group, alongside increases in several other cytokines; IL-1β increased in the steroid group on day 28.
- In survivors, dysregulated biomarkers showed improving trends, but most had not normalized by day 180.
- Markers associated with 90-day mortality differed between treatment groups, with few exceptions.
Why it matters
The findings show that circulating immune and cytokine markers in severe alcohol-associated hepatitis are dynamic rather than fixed, and that their trajectories may depend on treatment. This matters when interpreting biomarker measurements over time and when selecting or evaluating markers in clinical trials; a marker’s prognostic association may not generalize across treatment groups.
What to keep in mind
The analysis involved 89 patients with severe disease and followed biomarker levels through day 180; the abstract does not report whether these biomarker patterns predict clinical outcomes beyond the stated mortality associations.